SCHEMBL5546763

SCHEMBL5546763

CC(O)CNC(=O)c1c(O)c2ncc(Cc3ccc(F)cc3)cc2n(Cc2c[nH]cn2)c1=O

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TLR2 O60603 2/20 0.35
ACSS2 Q9NR19 2/20 0.34
EGLN3 Q9H6Z9 2/20 0.34
ALDH1A1 P00352 2/20 0.33
CNR1 P21554 1/20 0.33
HSD17B10 Q99714 1/20 0.33
USP2 O75604 1/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HIF1A Q16665 1/20 0.33
EGLN1 Q9GZT9 2/20 0.33
EGLN2 Q96KS0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546492 0.90 CNR2 (0.39) CNR2L3MBTL1MEN1KMT2ATLR2
SCHEMBL5545947 0.89 L3MBTL1 (0.38) CNR2L3MBTL1MEN1KMT2ATLR2
SCHEMBL5548095 0.88 L3MBTL1 (0.38) CNR2L3MBTL1MEN1KMT2ATLR2
SCHEMBL5543067 0.88 CNR2 (0.42) CNR2L3MBTL1MEN1KMT2ATLR2
SCHEMBL5545455 0.87 ALDH1A1 (0.46) CNR2L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL5541165 0.86 L3MBTL1 (0.52) CNR2L3MBTL1MEN1KMT2AACSS2
SCHEMBL5546991 0.85 CNR2 (0.51) CNR2L3MBTL1MEN1KMT2ATLR2
SCHEMBL5545774 0.85 CNR2 (0.42) CNR2L3MBTL1MEN1KMT2AACSS2
SCHEMBL5538489 0.85 POLB (0.45) CNR2L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL5545917 0.85 POLB (0.45) CNR2L3MBTL1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 CNR2 3954/4885L3MBTL1 1411/4885MEN1 4802/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 CNR2 4810/4885L3MBTL1 1408/4885MEN1 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.